Reverse remodeling in a heart failure patient with cardiomegaly treated with sacubitril/valsartan: a case report.

Sacubitril/valsartan (S/V) has shown promise as a tool for decreasing cardiovascular hospitalization and associated mortality among certain patients with heart failure and has been found to exhibit potential renoprotective and antiarrhythmic activity. This report is describing the case of a patient that suffered acute myocardial infarction within one month after undergoing percutaneous coronary intervention (PCI) stent implantation and who underwent standard guideline-directed medical treatment. Upon readmission, echocardiographic evaluation revealed enlargement of the left heart and reduced ejection fraction. While hospitalized, treatment with S/V was begun. Following sustained treatment with this drug for five months, the patient exhibited vascular remodeling, a 30% injection fraction improvement, a 15 mm reduction in left ventricular diastolic diameter, and a significant change in functional class from class III to I. Overall, this case report emphasizes the association between S/V treatment and reverse ventricular remodeling in a patient that experienced cardiomegaly following AMI.